

4b) inhibitor of vascular endothelial growth factor-mediated vascular permeability is not administered as part of the cardioplegia solution.


Applicant hereby elects Species 3A ("a single specific ischemic type e.g. 3a) myocardial infarction"), with traverse. Applicant requests reconsideration accordingly.

Applicant's election is made without prejudice. As noted by the Examiner, upon the allowance of a generic claim, Applicant will be entitled to consideration of claims to not more than a reasonable number of species in addition to the elected species, provided that all claims to each additional species are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.146.

An action on the merits of all the claims and a Notice of Allowance thereof are respectfully requested.

Dated: January 8, 2008

Respectfully submitted,

By 
Kathryn A. Piffat, Ph.D., Esq.

Registration No.: 34,901

EDWARDS ANGELL PALMER & DODGE
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 239-0100

Attorneys/Agents For Applicant